Key Highlights

• Cochlear reported its result for the year to 30 June 2026 on 18 August 2026.

• Sales Revenue was A$2,343.4 million, down 1% as reported and up 2% in constant currency.

• Second-half constant currency growth was 6%, which management presented as evidence of improving momentum.

• Underlying net profit fell 22% to A$322.4 million from A$414.5 million, and underlying Earnings Per Share were A$4.93.

Can Cochlear (ASX:COH) return to profit growth after a year in which earnings fell sharply but still landed at the top of reduced guidance? The company's FY27 outlook suggests a modest recovery, with underlying net profit guided to A$330 million to A$350 million, compared with A$322.4 million in FY26. That target depends on cost savings, the Nucleus Nexa rollout and a steadier operating environment, and it is guidance rather than a certainty.

The FY26 reset

Cochlear reported its result for the year to 30 June 2026 on 18 August 2026. Sales revenue was A$2,343.4 million, down 1% as reported and up 2% in constant currency. Second-half constant currency growth was 6%, which management presented as evidence of improving momentum.

Underlying net profit fell 22% to A$322.4 million from A$414.5 million, and underlying earnings per share were A$4.93.

The result followed a 22 April 2026 trading update in which the company cut its FY26 earnings guidance. Landing at the upper end of that revised range removed one source of uncertainty.

What Cochlear does and where revenue comes from

Cochlear makes implantable hearing devices, led by cochlear implants and the external sound processors that go with them. It also sells bone conduction and other acoustic implants, and provides services to existing recipients. Funding typically comes from insurers and government health programmes, so reimbursement policy matters a great deal.

FY26 revenue broke down as follows:

• Cochlear implants: A$1,435.2 million, flat in constant currency, with units up 5% to 56,692.

• Services: A$634.9 million, up 6%.

• Acoustics: A$273.3 million, up 1%.

More than 50,000 of the 800,000-plus recipients received a new sound processor during the year, which supports the services line.

Regional performance and margins

Results were uneven. US implant revenue rose 4% and Asia Pacific rose 7%, while Western Europe fell 8% and emerging markets slipped 2%. Within emerging markets, Latin America and Eastern Europe grew, while the Middle East and China declined.

Management pointed to several pressures: insurance pre-authorisation hurdles and household budget constraints in the US, healthcare capacity limits in parts of Europe, volume-based pricing in China, and conflict affecting Middle Eastern sales, which led to a A$10 million receivables provision.

Gross Margin fell to about 71% from 74%, reflecting product mix, under-absorbed overheads, currency and China pricing. Net margin dropped to 14% from 18%. Management still targets a return to an 18% net margin over the medium term, but has not set a date. On the guided figures, expense restraint rather than gross margin looks the main driver of any FY27 improvement.

Dividend and cash flow

The final Dividend was A$1.30 per share, down from A$2.15, taking the full-year dividend to A$3.45 from A$4.30. The company continues to target a payout of about 70% of underlying net profit. The final dividend was 85% franked.

Cash generation was a brighter spot. Management said free Cash Flow more than doubled on the prior year, helped by Working Capital and lower tax payments, and inventory fell by A$75 million in the second half. Capital Expenditure was A$91 million, with A$100 million to A$110 million guided for FY27.

Nexa, competition and the product pipeline

Nucleus Nexa now accounts for more than 95% of implant sales in developed markets, with an average price increase of about 3% that management says has held. It is also the platform intended for future products, including a drug-eluting electrode and a totally implantable cochlear implant. At the 26 October 2026 annual general meeting, the company said recruitment for pivotal studies of the totally implantable device had finished, while drug-eluting electrode results were being analysed and regulatory steps planned.

Competition is a live issue, particularly in acoustics, where Cochlear said it lost some share to increased competitor activity. It plans to launch a new Osia processor in FY27 to address this. In Germany, management said share was lost after a Nexa price increase preceded reimbursement cuts.

The longer-term argument rests on low penetration. Cochlear estimates adult clinical penetration at roughly 5%, so growth depends partly on referral pathways and clinical guidelines, which are being implemented in 25 countries.

FY27 guidance

For FY27 the company expects low single-digit constant currency revenue growth, a gross margin of 70% to 71%, a slight fall in reported operating expenses and R&D of about 13% of sales. The guidance assumes AUD/USD of 0.70 and AUD/EUR of 0.61, and the company expects a more encouraging Australian dollar to reduce underlying net profit by about 10% compared with FY26 average rates, after hedging.

Management also said fixed costs fell by about two percentage points of revenue in FY26. The AGM reaffirmed the A$330 million to A$350 million range. All resolutions passed, with the remuneration report receiving 96.43% support. Professor Ian Meredith joins the board as an independent non-executive director on 1 December.

Key risks and what to watch

Several uncertainties could affect delivery of the guidance:

• Currency: a more encouraging Australian dollar reduces translated earnings, and the hedging benefit is temporary.

• Reimbursement and pricing: policy changes in Germany, China and elsewhere can quickly change Volume and price.

• Competition: share losses in acoustics need to be reversed, and processor launches carry execution risk.

• Margins: recovery depends on mix, factory utilisation and pricing holding up.

• Pipeline: clinical and regulatory outcomes for new technologies are uncertain, and the Epiminder write-down shows investments can lose value.

• Restructuring: cost savings must be achieved without weakening growth investment, and the cloud program still has about A$60 million after tax to be expensed in FY27.

FY26 showed that earnings can move sharply when pricing, mix and currency shift together. FY27 is best seen as a test of whether the reset has stabilised the base.